Catalyst Pharmaceuticals (CPRX) Competitors $20.84 0.00 (0.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$21.00 +0.16 (+0.77%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CPRX vs. VRNA, RVMD, MRUS, GRFS, RYTM, CYTK, ABVX, RNA, NUVL, and LEGNShould you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Abivax (ABVX), Avidity Biosciences (RNA), Nuvalent (NUVL), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Catalyst Pharmaceuticals vs. Its Competitors Verona Pharma PLC American Depositary Share Revolution Medicines Merus Grifols Rhythm Pharmaceuticals Cytokinetics Abivax Avidity Biosciences Nuvalent Legend Biotech Catalyst Pharmaceuticals (NASDAQ:CPRX) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment. Is CPRX or VRNA more profitable? Catalyst Pharmaceuticals has a net margin of 37.36% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets Catalyst Pharmaceuticals37.36% 40.78% 35.36% Verona Pharma PLC American Depositary Share -36.62%-21.12%-9.07% Do analysts rate CPRX or VRNA? Catalyst Pharmaceuticals currently has a consensus price target of $33.20, suggesting a potential upside of 59.31%. Verona Pharma PLC American Depositary Share has a consensus price target of $109.00, suggesting a potential upside of 2.07%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Catalyst Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00Verona Pharma PLC American Depositary Share 1 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.07 Does the media favor CPRX or VRNA? In the previous week, Catalyst Pharmaceuticals had 8 more articles in the media than Verona Pharma PLC American Depositary Share. MarketBeat recorded 12 mentions for Catalyst Pharmaceuticals and 4 mentions for Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.58 beat Catalyst Pharmaceuticals' score of 0.56 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma PLC American Depositary Share 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals hold more shares of CPRX or VRNA? 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, CPRX or VRNA? Catalyst Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Which has better valuation and earnings, CPRX or VRNA? Catalyst Pharmaceuticals has higher revenue and earnings than Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCatalyst Pharmaceuticals$491.73M5.19$163.89M$1.6512.63Verona Pharma PLC American Depositary Share$42.28M217.70-$173.42M-$0.99-107.87 SummaryCatalyst Pharmaceuticals beats Verona Pharma PLC American Depositary Share on 14 of the 17 factors compared between the two stocks. Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPRX vs. The Competition Export to ExcelMetricCatalyst PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.55B$2.62B$6.11B$10.54BDividend YieldN/A56.38%5.66%4.70%P/E Ratio12.6324.2286.8126.71Price / Sales5.19530.20538.97202.98Price / Cash8.5228.3526.3031.09Price / Book3.425.3112.676.57Net Income$163.89M$32.78M$3.30B$276.78M7 Day Performance6.60%2.70%3.55%1.96%1 Month Performance2.71%8.77%6.79%9.11%1 Year Performance4.20%-3.79%72.30%31.60% Catalyst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPRXCatalyst Pharmaceuticals4.8571 of 5 stars$20.84flat$33.20+59.3%+4.2%$2.55B$491.73M12.6380Analyst DowngradeBuyback AnnouncementVRNAVerona Pharma PLC American Depositary Share1.92 of 5 stars$106.61-0.1%$109.00+2.2%+233.6%$9.19B$42.28M-107.6930Positive NewsRVMDRevolution Medicines4.286 of 5 stars$46.07+4.9%$74.64+62.0%-1.3%$8.61B$11.58M-10.24250MRUSMerus1.1145 of 5 stars$93.67+36.0%$92.73-1.0%+82.1%$7.08B$36.13M-17.0337Trending NewsAnalyst ForecastHigh Trading VolumeGRFSGrifols3.6257 of 5 stars$9.93+1.1%$10.30+3.7%+11.5%$6.83B$7.81B8.4923,822Positive NewsShort Interest ↑RYTMRhythm Pharmaceuticals3.5124 of 5 stars$100.64+1.5%$106.64+6.0%+99.5%$6.68B$130.13M-33.44140CYTKCytokinetics3.8721 of 5 stars$53.89+6.9%$75.71+40.5%+0.5%$6.45B$18.47M-10.57250Trending NewsAnalyst ForecastABVXAbivax3.1078 of 5 stars$83.33+0.6%$102.14+22.6%+758.1%$6.30BN/A0.0061RNAAvidity Biosciences2.5643 of 5 stars$42.63-0.7%$68.32+60.3%-0.6%$6.22B$10.90M-11.97190NUVLNuvalent3.261 of 5 stars$84.84+4.2%$119.50+40.9%-19.7%$6.12BN/A-17.3140LEGNLegend Biotech2.8143 of 5 stars$32.85-1.6%$74.22+125.9%-34.7%$6.06B$627.24M-37.332,609 Related Companies and Tools Related Companies VRNA Alternatives RVMD Alternatives MRUS Alternatives GRFS Alternatives RYTM Alternatives CYTK Alternatives ABVX Alternatives RNA Alternatives NUVL Alternatives LEGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CPRX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
